We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest market close, Humacyte, Inc. (HUMA - Free Report) reached $5.05, with a -1.94% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 1.86%. Meanwhile, the Dow lost 0.9%, and the Nasdaq, a tech-heavy index, lost 2.76%.
Prior to today's trading, shares of the company had lost 9.49% over the past month. This has lagged the Medical sector's loss of 3.61% and the S&P 500's gain of 1.01% in that time.
Market participants will be closely following the financial results of Humacyte, Inc. in its upcoming release. The company is expected to report EPS of -$0.25, unchanged from the prior-year quarter.
Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Humacyte, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 79, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUMA in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
In the latest market close, Humacyte, Inc. (HUMA - Free Report) reached $5.05, with a -1.94% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 1.86%. Meanwhile, the Dow lost 0.9%, and the Nasdaq, a tech-heavy index, lost 2.76%.
Prior to today's trading, shares of the company had lost 9.49% over the past month. This has lagged the Medical sector's loss of 3.61% and the S&P 500's gain of 1.01% in that time.
Market participants will be closely following the financial results of Humacyte, Inc. in its upcoming release. The company is expected to report EPS of -$0.25, unchanged from the prior-year quarter.
Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Humacyte, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 79, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUMA in the coming trading sessions, be sure to utilize Zacks.com.